Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.

Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DR.

Open Forum Infect Dis. 2014 May 22;1(1):ofu018. doi: 10.1093/ofid/ofu018. eCollection 2014 Mar.

2.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

PMID:
25461247
3.

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C.

Ann Intern Med. 2014 Jul 1;161(1):1-10. doi: 10.7326/M14-0293. Erratum in: Ann Intern Med. 2014 Aug 19;161(4):308.

4.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

PMID:
24842909
5.

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a.

6.

Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.

Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):25-32. doi: 10.1097/QAI.0000000000000095.

PMID:
24378728
7.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM.

Clin Infect Dis. 2013 Dec;57(11):1607-17. doi: 10.1093/cid/cit595. Epub 2013 Sep 17.

8.

Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.

Johnson BA, Ribaudo H, Gulick RM, Eron JJ Jr.

Biometrics. 2013 Sep;69(3):732-40. doi: 10.1111/biom.12064. Epub 2013 Jul 17.

9.

Invasive meningococcal disease in men who have sex with men.

Simon MS, Weiss D, Gulick RM.

Ann Intern Med. 2013 Aug 20;159(4):300-1. doi: 10.7326/0003-4819-159-4-201308200-00674. No abstract available.

10.
11.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.

Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b.

12.

Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti.

Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD Jr, Pape JW, Fitzgerald DW.

J Int AIDS Soc. 2012 Jun 14;15(2):17375. doi: 10.7448/IAS.15.2.17375.

13.

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR.

J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4.

14.

Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.

Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR.

HIV Clin Trials. 2012 Jan-Feb;13(1):1-10. doi: 10.1310/hct1301-001.

15.

Novel clinical trial designs for the development of new antiretroviral agents.

Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K.

AIDS. 2012 May 15;26(8):899-907. doi: 10.1097/QAD.0b013e3283519371. Review.

16.

Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR.

Antimicrob Agents Chemother. 2012 Apr;56(4):1931-5. doi: 10.1128/AAC.06061-11. Epub 2012 Jan 17.

17.

Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.

Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A Path Towards Personalized HIV Care.

HIV Clin Trials. 2011 Sep-Oct;12(5):277-85. doi: 10.1310/hct1205-277. No abstract available.

18.

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM.

J Virol. 2012 Jan;86(2):1119-28. doi: 10.1128/JVI.06421-11. Epub 2011 Nov 16.

19.

CCR5 antagonism in HIV infection: current concepts and future opportunities.

Wilkin TJ, Gulick RM.

Annu Rev Med. 2012;63:81-93. doi: 10.1146/annurev-med-052010-145454. Epub 2011 Oct 27. Review.

20.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk